CERENOVUS Receives European Regulatory Approval For BRAVO Flow Diverter to Treat Intracranial Aneurysms.
CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received European CE mark approval for its BRAVO Flow Diverter. The device is approved for use in the treatment of patients suffering from intracranial aneurysms. The device will divert blood flow from the aneurysm and promote healing thereby reducing the risk of rupture, a main cause of hemorrhagic stroke.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180808005446/en/
The BRAVO Flow Diverter marks CERENOVUS’ entry into the flow diverter category, adding to its broad portfolio of devices used in endovascular treatment of hemorrhagic and ischemic stroke. The innovative design of the device aims to improve clinician ease of use, improve cost effectiveness and reduce length of procedure.
“Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms” explains Professor Patrick Brouwer Senior Consultant Neurointerventionalist at Karolinska University Hospital and Evaluator for BRAVO Flow Diverter. “I believe the design of the BRAVO Flow Diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms.”
Stroke is a devastating disease that strikes 15 million people each year,1 with hemorrhagic strokes accounting for 13%2 of all strokes. Aneurysms are a main cause of hemorrhagic strokes and occur when a weakened region of a blood vessel balloons until it ruptures and bleeds into the brain.2
“The BRAVO Flow Diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke” said Daniella Cramp, CERENOVUS Worldwide President. “Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke”.
Early evaluations are scheduled to take place across Europe ahead of European commercialization.
The device is currently not approved for use in the United States.
- ENDS -
About CERENOVUS
CERENOVUS, part of the Johnson & Johnson
Medical Devices Companies, is a global leader in neurovascular care. Our
commitment to changing the trajectory of stroke is inspired by our long
heritage and dedication to helping physicians protect people from a
lifetime of hardship. CERENOVUS offers a broad portfolio of devices used
in the endovascular treatment of hemorrhagic and ischemic stroke.
About the Johnson & Johnson Medical Devices Companies
The
Johnson & Johnson Medical Devices Companies' purpose is to reach more
patients and restore more lives. Having advanced patient care for more
than a century, these companies represent an unparalleled breadth of
products, services, programs and research and development capabilities
in surgical technology, orthopaedics, cardiovascular and specialty
solutions with an offering directed at delivering clinical and economic
value to health care systems worldwide.
References
1. The Economist Intelligence Unit (2016) Addressing the global stroke burden. [Online]. https://perspectives.eiu.com/sites/default/files/Addressingtheglobalstrokeburden_0.pdf. Last accessed May 2, 2018.
2. American Stroke Association (2018) Hemorrhagic Strokes (Bleeds). [Online]. http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/HemorrhagicBleeds/Hemorrhagic-Strokes-Bleeds_UCM_310940_Article.jsp#.WypwpFVKjIW. Last accessed June 20, 2018.
© CERENOVUS 2018. All rights reserved.095543-180723
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180808005446/en/
Contact information
CERENOVUS
REBECCA RATCLIFFE
+44 (0) 7825 378894
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BGO Announces US$5.1 Billion Capital Raise for Its Asia Value-Add Real Estate Strategy, Marking Largest Closed-End Fundraise in Firm’s History5.6.2025 23:00:00 EEST | Press release
BGO today announced the final close of BentallGreenOak Asia IV (“BGO Asia Fund IV” or the “Fund”), its flagship Asia-focused value-add real estate strategy, raising over US$5.1 billion in total capital commitments for the Fund and co-investment sidecars. The Fund represents the largest closed-end capital raise in BGO’s history, underscoring the firm’s history and reputation as a premier global real estate investment manager in Asian markets. BGO Asia Fund IV targets value-add opportunities in office, hospitality, and logistics assets across Japan, South Korea, Australia, and Singapore. Japan represents a central pillar of our investment strategy, driven by regulatory reforms and corporate governance shifts that are catalyzing an estimated US$3 trillion in non-core asset divestitures. “Japan is undergoing a profound transformation, and we see strong, sustained tailwinds across the region,” said Fred Schmidt, Managing Partner and Chairman of Asia, BGO. “Tokyo is one of the world’s larges
PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 20:00:00 EEST | Press release
PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football clubs, bringing together champions from all six FIFA confederations for a month-long tournament in 11 cities across the U.S. Romy Gai, Chief Business Officer at FIFA, said:“We are delighted to welcome PIF as a partner of the FIFA Club World Cup 2025™. Together, we look forward to delivering a historic tournament that inspires and unites fans from around the wo
Orange Logic Appoints Ben Colenso as Managing Director, EMEA5.6.2025 19:41:00 EEST | Press release
Orange Logic, the leader in digital asset management and content orchestration, today announced the appointment of Ben Colenso as Managing Director for EMEA. Based in the UK, Colenso will spearhead Orange Logic’s regional strategy, customer enablement, and market expansion efforts, as the company accelerates its global footprint. Colenso brings 20 years of experience in technology and media production, having most recently led the technology strategy for Hogarth, WPP’s content experience company. Known for solving complex problems for some of the world’s most iconic brands with his customer-centric approach, Colenso will play a critical role in strengthening Orange Logic’s presence and partnerships across EMEA which span customers such as ITV, Pearson, GSK, Ubisoft and Tourism Ireland amongst others. “Ben’s appointment reflects our deep commitment to EMEA, where we continue to see strong momentum and increasing demand from some of the world’s most sophisticated enterprises,” said Brian
Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20405.6.2025 18:22:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has extended full support coverage for all SAP ECC 6.0 and S/4HANA releases through 2040, without any need to complete a migration to S/4HANA on RISE as required by SAP for clients who want to remain on SAP’s Annual Support and receive full support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605581964/en/ Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 2040 Rimini Street SAP Clients Gain Long-Term Savings to Self-Fund Innovation Current Rimini Support™ for SAP clients are not impacted by SAP’s end-of-maintenance dates. With unmatched support, service and guidance from Rimini Street as a single, trusted partner – clients can keep systems r
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform5.6.2025 17:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive global patent strategy and highlights the innovation and international recognition of the company’s proprietary technologies. RenMab™ mice are a core member of Biocytogen’s independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom